RLAY Relay Therapeutics, Inc.

17.95USD-4.22%Mkt Cap: 3.93B $P/E: —

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It transforms the drug discovery process with a focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic …

Key Statistics

Company
Market Cap3.93B USD
Enterprise Value3.23B USD
Revenue (TTM)10.35M USD
Gross Profit-258.50M USD
Net Income (TTM)-276.48M USD
Revenue/Share0.06 USD
Last Price17.95 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees202
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.48
PEG—
EV/EBITDA-10.47
EV/Revenue311.73
P/S396.78
P/B4.60
EPS (TTM)-1.51
EPS (Forward)-1.63
52W Range
4.32080% of range21.27
52W High21.27 USD
52W Low4.320 USD
Profitability
Gross Margin0.00%
Oper. Margin-25949.72%
EBITDA Margin0.00%
Profit Margin-1800.58%
ROE-48.76%
ROA-44.50%
Growth
Revenue Growth-48.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF-235.46M USD
CapEx (TTM)410.00K USD
FCF Margin-1152.10%
FCF Yield-3.03%
Net Debt-880.28M USD
Net Debt/EBITDA2.86
Balance Sheet
Debt/Equity0.06
Current Ratio18.27
Quick Ratio17.93
Book Value/Sh4.07 USD
Cash/Share4.16 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.58 USD
Upside (mean)+53.7%
Target Range20.00 USD – 32.00 USD
20.00+53.7% to mean32.00
# Analysts12
Ownership
Shares Out.219.14M
Float145.48M
Insiders1.61%
Institutions110.84%
Short Interest
Short Ratio15.3d
Short % Float23.64%
Short % Out.20.30%
Shares Short44.49M
Short (prev mo.)41.36M
Technical
SMA 5019.11 (-6.1%)
SMA 20014.06 (+27.6%)
Beta1.73
S&P 52W Chg16.45%
Avg Vol (30d)3.18M
Avg Vol (10d)3.17M
Technical Indicators
RSI (14)43.5
MACD-0.1503
MACD Signal-0.1781
MACD Hist.+0.0277
BB Upper19.74 USD
BB Middle18.58 USD
BB Lower17.43 USD
BB Width12.43%
ATR (14)0.9542 USD
Vol Ratio (20d)0.95x